NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Reviewed May 26, 2026

Tirzepatide

Prescription ·Strong evidence ·Reviewed May 2026

Prescription dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist used for type 2 diabetes and chronic weight management when prescribed under an FDA-approved label.

What it's good for
  • Lowers HbA1c in type 2 diabetes2,3
  • Substantial weight loss in chronic weight-management trials5,1
  • Once-weekly subcutaneous administration1,2
  • Low intrinsic hypoglycemia risk as monotherapy, but risk rises with insulin or sulfonylureas
What to watch for
  • Nausea
  • Vomiting
  • Diarrhea
  • Personal or family history of medullary thyroid carcinoma (MTC)4
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)

The bottom line

Evidence rating strong. Most-documented uses: lowers hba1c in type 2 diabetes, substantial weight loss in chronic weight-management trials, once-weekly subcutaneous administration. 5 sources indexed (2021–2026), with 6 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Activates GIP and GLP-1 receptors, increasing glucose-dependent insulin secretion, lowering glucagon, slowing gastric emptying, reducing appetite, and improving glycemic control and body weight in indicated populations.3

Class
Dual GIP/GLP-1 Receptor Agonist
Dosing

Dosing & protocol.

Common range
2.5-15 mg subcutaneous injection once weekly, titrated per prescribing information
Recommended form
FDA-approved prefilled pen or vial/syringe product prescribed by a clinician

Subcutaneous prescription medication; food timing is not the primary driver of exposure.

Safety

Full safety detail.

Side effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain or dyspepsia
  • Injection-site reactions
  • Hypoglycemia when combined with insulin or sulfonylureas
  • Pancreatitis and gallbladder disease have been reported

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)4
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • Known serious hypersensitivity to tirzepatide or product excipients1,2
  • Pregnancy or planned pregnancy unless directed by the prescribing clinician
Interactions

Interaction records.

SeriousCaution

Berberine

Both tirzepatide and berberine can lower blood glucose through complementary mechanisms, creating a clinically important hypoglycemia risk when combined, especially if insulin or sulfonylureas are also used.

Recommendation: Do not add berberine to tirzepatide therapy without prescriber supervision. If both are used, monitor blood glucose closely during initiation and dose changes and carry fast-acting glucose.

ModerateCaution

Alpha-Lipoic Acid

Alpha-lipoic acid may improve insulin sensitivity and lower glucose, which can add to tirzepatide's glucose-lowering effects.

Recommendation: Use caution when combining alpha-lipoic acid with tirzepatide. Monitor blood glucose more often when starting or changing alpha-lipoic acid, especially if also taking insulin or sulfonylureas.

ModerateCaution

Chromium

Chromium may enhance insulin signaling and glucose metabolism, adding to tirzepatide's glucose-lowering effect.

Recommendation: Low-dose chromium in a multivitamin is usually low risk. Use caution with high-dose chromium supplements and monitor glucose when starting or changing dose.

ModerateCaution

Fenugreek

Fenugreek can lower glucose and slow carbohydrate absorption, while tirzepatide lowers glucose and slows gastric emptying. Combining them can worsen nausea, bloating, constipation, or hypoglycemia risk in susceptible users.

Recommendation: Tell your prescriber before combining fenugreek with tirzepatide. Monitor glucose for 2-4 weeks and stop or reduce fenugreek if GI symptoms worsen.

InfoSynergy

Ginger Extract

Ginger may help nausea during tirzepatide titration. It does not address severe or persistent GI symptoms, dehydration, or pancreatitis warning signs.

Recommendation: For mild nausea, ginger tea or modest supplemental ginger with meals may be reasonable. Seek medical guidance for persistent vomiting, severe abdominal pain, dehydration, or inability to keep fluids down.

InfoSynergy

Psyllium Husk

Psyllium can complement tirzepatide for postprandial glucose and constipation support, but additive GI slowing can worsen bloating or early satiety.

Recommendation: Increase psyllium gradually with plenty of water. Pause or reduce if bloating, constipation, or early satiety worsens during tirzepatide titration.

Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Randomized controlled trials

3

Reference material

2
  • 4ZEPBOUND (tirzepatide) prescribing informationSource linkedURLDailyMed / U.S. National Library of Medicine · DailyMed · 2026

    Labeling includes a boxed warning about thyroid C-cell tumors in rats and contraindication with personal/family history of MTC or MEN 2.

  • 5FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossSource linkedURLU.S. Food and Drug Administration · FDA · 2026

    FDA warns that unapproved GLP-1 versions, including semaglutide and tirzepatide products, do not undergo FDA review for safety, effectiveness, or quality.

Keep exploring

Deep dives & adjacent profiles.

This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.

Use this with your stack

Tirzepatide in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.